Cellusion’s core technologies are centered on the regenerative medicine technologies of differentiation induction and cell culture for producing CECSi cells, corneal endothelial cell substitute from iPSC, which were developed by Professor Shigeto Shimmura (currently of Fujita Health University) and Shin Hatou (Cellusion CEO) at the Department of Ophthalmology, Keio University School of Medicine. Over the medium to long term, we will develop technologies for regenerative medicines that will enable us to create unique value propositions different from those offered by conventional pharmaceuticals based on a patient-centric approach by exploring synergy with related technology fields, such as genome editing and biomaterial engineering.
In parallel, Cellusion will continue to explore fundamental technologies for regenerative medicine, both in-house and in collaboration with academic institutions.